Monograph Details
|
|
Eye Disorders
> Glaucoma
|
|
TIMOPTIC OCUDOSE |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Noncardioselective β-blocker. |
| Generic Name |
|
Timolol (as maleate) 0.25%, 0.5%; (0.2mL/dose); oph soln; preservative-free. |
| Also |
• TIMOPTIC
• TIMOPTIC-XE
|
| Indications |
|
Open-angle glaucoma. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 1 drop of 0.25% twice daily; max 1 drop of 0.5% twice daily. Transfer from other drugs, see literature. |
| Contraindications |
|
Greater than 1st-degree AV block. Uncompensated cardiac failure. Cardiogenic shock. Sinus bradycardia. History of bronchospasm. Bronchial asthma. Severe COPD. As sole agent in narrow-angle glaucoma. All contact lenses (Timoptic-XE); soft contact lenses (Timoptic and Timoptic-XE). |
| Precautions |
|
Poor cardiac reserve should be controlled with digitalis and diuretics. Diabetes. Presbyopia. May mask hypoglycemia or thyrotoxicosis. Myasthenia gravis. Cerebrovascular insufficiency. Measure intraocular pressure after 4 weeks of treatment. Avoid abrupt cessation. Discontinue at 1st sign of cardiac failure and before surgery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
May potentiate systemic β-blockers, reserpine, hypoglycemics and mydriatic effect of topical epinephrine. Additive cardiac and pulmonary effects with anticholinesterase miotics. May antagonize bronchodilation from β-adrenergic agonists. May cause conduction defects with calcium channel blockers, digoxin. |
| Adverse Reactions |
|
Ocular irritation, sensitization, rash, dizziness, blurred vision, corneal anesthesia, headache, GI upset, paresthesias. Systemic β-blocker effects (bradycardia, arrhythmias, hypotension, bronchospasm, heart failure). Aphakic maculopathy (rare). |
| How Supplied |
Soln—5mL, 10mL, 15mL
Ocudose—60
XE—2.5mL, 5mL |
|
|
|
|
